Evaluation of Betaxolol in improving the acute phase of patients with mild to moderate Traumatic Brain Injury

Evaluation of Betaxolol in improving the Glasgow Outcome Scale Extended (GOSE) of the acute phase of patients with mild to moderate Traumatic Brain Injury: A double blinded randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240415061488N1

Enrollment

104

Registered

2024-04-25

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury. Intracranial injury

Interventions

Intervention 1: Intervention group: Taking Betaxolol Hydrochloride 5mg, Oral, Single Dose, This drug is given to the patients of the intervention group one time after admission to the hospital. Interv

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with mild to moderate traumatic brain injury (GCS score of 9 or above) Age 18 to 65 years old

Exclusion criteria

Exclusion criteria: Patients with penetrating head trauma Unspecified time of trauma Patients with spinal cord injury Patients with cardiovascular diseases Hemodynamic instability Candidates for craniotomy

Design outcomes

Primary

Measure	Time frame
Score of Glasgow Outcome Scale Extended (GOSE). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Glasgow Outcome Scale Extended (GOSE) Questionnaire.	—

Secondary

Measure	Time frame
Score of The Working Memory Questionnaire. Timepoint: Day 1 and 14 after taking medication. Method of measurement: The Working Memory Questionnaire.;Score of Visual analogue scale (VAS). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Visual analogue scale (VAS).;Score of Mini Mental State Examination (MMSE). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Score of Mini Mental State Examination (MMSE).;Presence of drug side effects. Timepoint: Day 1 and 14 after taking medication. Method of measurement: If the patient confirms any side effects of the drug "Yes" otherwise "No".	—

Measure

Time frame

Score of The Working Memory Questionnaire. Timepoint: Day 1 and 14 after taking medication. Method of measurement: The Working Memory Questionnaire.;Score of Visual analogue scale (VAS). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Visual analogue scale (VAS).;Score of Mini Mental State Examination (MMSE). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Score of Mini Mental State Examination (MMSE).;Presence of drug side effects. Timepoint: Day 1 and 14 after taking medication. Method of measurement: If the patient confirms any side effects of the drug "Yes" otherwise "No".

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMousareza Anbarlouei

Bagheiat-allah University of Medical Sciences

Mousareza.anbarlouei@bmsu.ac.ir+98 21 8126 3999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026